Keyphrases
Steatohepatitis
100%
Liver Fibrosis
100%
Monocyte Recruitment
100%
Cenicriviroc
100%
Inflammatory Monocytes
100%
Therapeutic Inhibitors
100%
Nonalcoholic Steatohepatitis
75%
CCR2
62%
Macrophages
37%
Kupffer Cells
37%
Liver Fibrosis Progression
37%
Insulin Resistance
25%
Hepatic Fibrosis
25%
Chemokine Receptor
25%
Ly6C
25%
Obesity
12%
Triglyceride Level
12%
Inflammation
12%
Therapeutic Treatment
12%
Growth Factors
12%
Hepatocytes
12%
Pharmacological Inhibitors
12%
Monocyte-derived Macrophages
12%
Infiltration
12%
Therapeutic Potential
12%
Monocytes
12%
RNA-seq Analysis
12%
Mouse Model
12%
Human Liver
12%
Human Disease
12%
Therapeutic Effect
12%
Hepatic Inflammation
12%
Lipid Metabolism
12%
Cell-derived
12%
Fibrosis Stage
12%
Monocyte-derived Cells
12%
Clinical Evaluation
12%
Stellate Cell Activation
12%
Hepatology
12%
Fibrosis Regression
12%
Phagocytes
12%
Fatty Acid Metabolism
12%
CCR5 Antagonist
12%
Fibrosis Progression
12%
Monocyte Infiltration
12%
Liver Macrophages
12%
Macrophage Polarization
12%
Human Liver Tissue
12%
Hepatic Fat
12%
Fibrosis Resolution
12%
Activated Pathways
12%
Fibrotic Steatohepatitis
12%
Cluster of Differentiation 68
12%
Medicine and Dentistry
Liver Fibrosis
100%
Cenicriviroc
100%
Steatohepatitis
100%
Chemokine Receptor
87%
Nonalcoholic Fatty Liver
75%
Fibrosis
62%
Macrophage
62%
Kupffer Cell
37%
Insulin Resistance
25%
Triacylglycerol
12%
Clinical Trial
12%
RNA Sequence
12%
Cytokine
12%
Cell Activation
12%
Hepatocyte
12%
Growth Factor
12%
Lipid Metabolism
12%
Stellate Cell
12%
Hepatology
12%
Liver Tissue
12%
Therapy Effect
12%
Macrophage Polarization
12%
Fatty Acid Metabolism
12%
Experimental Steatohepatitis
12%
Chemokine Receptor CCR5 Antagonist
12%
Diseases
12%
Oral
12%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Fibrosis
100%
Cenicriviroc
100%
Chemokine Receptor
87%
Nonalcoholic Fatty Liver
75%
Fibrosis
62%
Inflammation
25%
Insulin Resistance
25%
Triacylglycerol
12%
Fatty Acid
12%
Cytokine
12%
RNA-Sequencing
12%
Clinical Trial
12%
Mouse Model
12%
Growth Factor
12%
Therapeutic Effect
12%
Experimental Steatohepatitis
12%
Chemokine Receptor CCR5 Antagonist
12%
Diseases
12%
Immunology and Microbiology
Steatohepatitis
100%
Chemokine Receptor
63%
Macrophage
45%
Kupffer Cell
27%
Insulin Resistance
18%
CCR5
9%
Growth Factor
9%
RNA Sequence
9%
Cytokine
9%
Cell Activation
9%
Mouse Model
9%
Lipid Metabolism
9%
Experimental Model
9%
Stellate Cell
9%
Liver Tissue
9%
Phagocyte
9%
Hepatology
9%
Triacylglycerol Level
9%
Cluster of Differentiation
9%
Fatty Acid Metabolism
9%
Macrophage Polarization
9%